Search Results
Oct 06, 2025, 17:14 ET ESSA Securityholders Approve Acquisition by XenoTherapeutics
to the completion of the Transaction; (ii) potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto; (iii) potential exposure or liability
More news about: ESSA Pharma Inc
Sep 30, 2025, 16:30 ET ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
www.xenotx.org. About XOMA Royalty Corporation XOMA Royalty is a biotechnology royalty aggregator that has an extensive and growing portfolio of assets (asset defined
More news about: ESSA Pharma Inc.
Sep 29, 2025, 14:39 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
options. Mural Oncology plc (NASDAQ: MURA)'s sale to XOMA Royalty Corporation for $2.035 per share and up to an additional $0.205 per share under certain conditions. If you are a Mural shareholder,
More news about: Halper Sadeh LLP
Sep 27, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - AMWD, PHLT, ARIS, and MURA
MURA) related to its sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, Mural shareholders will receive $2.035 in cash per share and, up to an additional
More news about: Monteverde & Associates PC
Sep 24, 2025, 06:00 ET ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) continues to act as structuring agent and intends to provide financing for the transaction (the "Transaction"). Under
More news about: ESSA Pharma Inc.
Sep 23, 2025, 13:51 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBAN, HBI, NWE, MURA on Behalf of Shareholders
click here to learn more about your rights and options. Mural Oncology plc (NASDAQ: MURA)'s sale to XOMA Royalty Corporation for $2.035 per share and up to an additional $0.205 per share under
More news about: Halper Sadeh LLP
Sep 22, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - GTLS, PHLT, ARIS, and MURA
MURA) related to its sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, Mural shareholders will receive $2.035 in cash per share
More news about: Monteverde & Associates PC
Sep 10, 2025, 06:00 ET Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
the date of the Special Meeting to change; (iii) potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto; (iv) the risk that disruptions
More news about: ESSA Pharma Inc.